MARKET

CLSD

CLSD

Clearside
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.560
-0.160
-5.88%
Closed 16:00 05/10 EDT
OPEN
2.680
PREV CLOSE
2.720
HIGH
2.840
LOW
2.550
VOLUME
111.39K
TURNOVER
--
52 WEEK HIGH
4.530
52 WEEK LOW
1.250
MARKET CAP
147.40M
P/E (TTM)
-6.5810
1D
5D
1M
3M
1Y
5Y
Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its first quarter 2021 financial...
GlobeNewswire · 6d ago
Analysts Are Bullish on These Healthcare Stocks: Clearside Biomedical (CLSD), Krystal Biotech (KRYS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clearside Biomedical (CLSD) and Krystal Biotech (KRYS) with
SmarterAnalyst · 05/03 16:05
BRIEF-Clearside Biomedical Announces Resubmission Of New Drug Application For Xipere For Treatment Of Macular Edema Associated
reuters.com · 05/03 12:20
Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE for Treatment of Macular Edema Associated with Uveitis
GlobeNewswire · 05/03 12:05
Clearside Biomedical resubmits eye treatment XIPERE NDA
Clearside Biomedical (CLSD) announces the resubmission of its New Drug Application ((NDA)) to the U.S. FDA for eye drug XIPERE for the treatment of macular edema associated with uveitis.The company had received
Seekingalpha · 05/03 11:36
Clearside Biomedical Resubmits New Drug Application for Xipere
MT Newswires · 05/03 08:35
Global Placenta Growth Factor Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Placenta Growth Factor market report provides a detailed analysis of global market size, regional and country-level...
Heraldkeepers · 04/15 11:59
Global Placenta Growth Factor Market Insights, Overview, Analysis and Forecast 2015-2026
Heraldkeepers · 04/14 06:34
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLSD. Analyze the recent business situations of Clearside through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLSD stock price target is 6.38 with a high estimate of 8.00 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 81
Institutional Holdings: 17.02M
% Owned: 29.56%
Shares Outstanding: 57.58M
TypeInstitutionsShares
Increased
10
1.84M
New
7
144.52K
Decreased
10
332.92K
Sold Out
7
156.68K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.01%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chairman/Independent Director
Christy Shaffer
President/Chief Executive Officer/Director
George Lasezkay
Chief Financial Officer
Charles Deignan
Independent Director
Richard Croarkin
Independent Director
Jeffrey Edwards
Independent Director
William Humphries
Independent Director
Nancy Hutson
Independent Director
Clay Thorp
No Data
About CLSD
Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting three components of the eye: the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision; the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment, and the sclera, which is the outer protective layer of the eye. The Company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide formulated for administration via suprachoroidal injection.

Webull offers kinds of Clearside Biomedical Inc stock information, including NASDAQ:CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLSD stock methods without spending real money on the virtual paper trading platform.